Search
Simcere Simian and NextCure Form Strategic Alliance to Develop ADC Novel Drug SIM0505
2025-06-17 /
Read about 0 minute
Author：小编
Simcere Simian and NextCure have announced a strategic collaboration aimed at advancing SIM0505, an innovative antibody-drug conjugate (ADC) targeting CDH6 for the treatment of solid tumors. Currently in Phase I clinical trials in China, SIM0505 is scheduled to commence corresponding clinical trials in the United States during the third quarter of 2025, with preliminary data anticipated for release in the first half of 2026.
Under the terms of the agreement, NextCure will secure exclusive global rights to SIM0505 (excluding Greater China), and leverage Simcere Simian's proprietary technology to develop new target ADCs. Simcere Simian will maintain its related rights and benefits within Greater China.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
